OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers Research & Therapy is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	167
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	162
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	160
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	129
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	119
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	116
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	116
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	101
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	100
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data	91
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	90
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	88
Longitudinal change in hippocampal and dorsal anterior insulae functional connectivity in subjective cognitive decline	87
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	87
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	83
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	78
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	76
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	74
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	71
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	71
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	69
Predict Alzheimer’s disease using hippocampus MRI data: a lightweight 3D deep convolutional network model with visual and global shape representations	66
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	65
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217	62
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	62

Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	61
Dynamic reciprocal relationships between cognitive and functional declines along the Alzheimer’s disease continuum in the prospective COGICARE study	60
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	60
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	58
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	55
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	55
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia	55
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog	52
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	52
Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design	50
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	50
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	49
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	49
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	49
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	49
Serum neurofilament light chain level as a predictor of cognitive stage transition	48
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort	48
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6	48
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	47
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	47
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	46
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	46
Divergent brain regional atrophy and associated fiber disruption in amnestic and non-amnestic MCI	46
Cross-cultural effects of reminiscence therapy on life satisfaction and autobiographical memory of older adults: a pilot study across Mexico and Spain	46